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Disease-free survival of adjuvant 
sunitinib following nephrectomy: results 
of the S-TRAC phase III trial
Currently, the tyrosine kinase inhibitor sunitinib is on-
ly given in case of advanced or metastatic renal cell car-
cinoma (mRCC). This randomized, double-blind phase 
III trial examined the efficacy and safety of sunitinib vs. 
placebo in patients with locoregional RCC who under-
went nephrectomy and are at high risk of tumor recur-
rence. Treatment-naïve patients with locoregional RCC 
(≥T3 and/or N1–2, no metastases; N = 615) received a 
daily dose of 50mg sunitinib (N= 309) or placebo (N= 
306) q4w-on/2w-off for 1 year until disease recurrence, 
occurrence of secondary malignancy, significant toxici-
ty, or consent withdrawal.1 The primary endpoint of the 
study was disease-free survival (DFS), while secondary 
objectives included, overall survival (OS), safety, and 
patient-reported outcomes. The reported median DFS 
of 6.8 months (95%CI[5.8 months – not reached]) with 
sunitinib was significantly longer than the mDFS of 5.6 
months (95%CI[3.8 months –6.6 months]) seen with 
placebo (Hazard Ratio [HR] = 0.76 [0.59 – 0.98]; p= 
0.030; Figure 1). No OS data were presented at this time. 
Grade ≥3 adverse events (AEs) were more frequent with 
sunitinib (62.1%) than with placebo (21.1%) although 
no difference was observed in the frequency of serious 
AEs (21.9% vs. 17.1%, respectively). 
These data might indicate that sunitinib is a potential 
adjuvant therapy in this cohort of patients.1 However, 
these results are contradictory to what was reported in 
the ASSURE trial. A possible explanation for this differ-
ence might be that in the S-TRAC trial no T1-2 tumors 
were included, less dose reduction of sunitinib was al-
lowed and no patients with non clear-cell RCC were en-
rolled.2 As such, more data are needed before sunitinib 
could be considered as a standard adjuvant therapy fol-
lowing nephrectomy.
Shift in initial targeted therapy in mRCC? 
Findings from the phase II ALLIANCE 
A031203 trial
Cabozantinib, an oral, potent inhibitor of MET, AXL 
and VEGFR2, has previously shown its potential as sec-
ond-line therapy in mRCC patients after prior VEGF-tar-
geted therapy.3,4 The goal of the presented randomized 
phase II multicenter trial was to assess the efficacy of 
cabozantinib as frontline targeted therapy in patients 
with mRCC. Treatment-naïve patients (clear-cell mRCC, 
ECOG performance status 0-2, and intermediate or poor 
risk according to the Heng criteria; N=157) were ran-
domized 1:1 to receive either cabozantinib (60 mg dai-
ly), or sunitinib (50 mg daily, q4w-on/2w-off). Patients 
were stratified for risk groups and the presence of bone 
metastases. The objective response rate (ORR, accord-
ing to RECIST v1.1) was 46% for cabozantinib vs. 18% 
for sunitinib. The median progression-free survival (PFS) 
was significantly higher in the cabozantinib cohort (8.2 
months, 95%CI[6.2 months – 8.8 months]) compared 
to the sunitinib cohort (5.6 months, 95%CI[3.4 months 
– 8.2 months]). This corresponds with a 31% reduc-
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The central theme of ESMO 2016 was ‘From disease treatment to patient care’, and the congress aimed 
at further integrating clinical research with patient needs. This report will highlight 9 key studies 
concerning renal cell carcinoma and metastatic prostate cancer, some of which were presented during 
one of the presidential sessions of the meeting. 
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 No. at Risk:
 Sunitinib 309 225 173 153 144 119 53 10 3 0
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Median DFS, y (95% CI)
Sunitinib 6.8 (5.8-NR)
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P=0.030*
HR 0.761 (95% CI, 0.594-0.975)
Figure 1. DFS for sunitinib versus placebo as adjuvant therapy in high-risk RCC following nephrectomy.1 A significant 
difference was observed in DFS between adjuvant sunitinib and placebo in high-risk RCC following nephrectomy.
tion in risk of disease progression or death with cabo-
zantinib (adjusted HR[95%CI]: 0.69[0.48 – 0.99], p= 
0.012; Figure 2A). The benefit of cabozantinib was es-
pecially prominent in patients with bone metastases 
(HR[95%CI]: 0.51[0.29 – 0.90]), but was not observed 
in any of the other subgroups. No difference was ob-
served with respect to OS (median OS 26.4 months vs. 
23.5 months; adjusted HR[95%CI]: 0.87[0.55 – 1.4]; 
Figure 2B). The toxicity profile also proved to be similar 
for both TKIs, with 70.5% and 72.2% grade ≥3 AEs for 
cabozantinib and sunitinib respectively. Although these 
data favor for cabozantinib as first-line targeted thera-
py in mRCC, larger comparative studies are needed in 
order to adapt the current standard therapy. Also the 
specific toxicity profile of cabozantinib requires further 
follow-up should it be implemented as first-line therapy.5
Combination of targeted therapies in 
various solid tumors
Combining different therapies often leads to an im-
proved efficacy when compared to monotherapy. In 
this light, combining a kinase inhibitor with an im-
mune-checkpoint inhibitor has the potential to im-
prove patient outcomes. At ESMO 2016, several ongoing 
phase I trials were presented that are investigating this 
hypothesis.
Firstly, an ongoing, open-label, multicenter, phase 
1b trial assessed the maximum tolerated dose, safe-
ty, tolerability, and ORR (irRECIST) of lenvatinib plus 
pembrolizumab in metastatic solid tumors. Thirteen pa-
tients were enrolled (2 non-small cell lung carcinomas 
[NSCLC], 8 RCC: 2 endometrial carcinomas, and 1 mel-
anoma) and received pembrolizumab (200mg IV q3w) 
and 1 of 2 lenvatinib dose levels (DL, orally daily): DL1 
= 24mg (N=3), or DL2 = 20mg (N=10). Two dose lim-
iting toxicities were reported for DL1, while none were 
observed with DL2. All patients experienced at least 1 
treatment-related AE. DL1 was associated with an ORR 
of 100% (all partial responses [PR]), while DL2 showed 
an ORR of 40% (all PR). PRs were reported for 4 RCC, 1 
NSCLC, 1 endometrial carcinoma, and 1 melanoma. In 
conclusion, the authors stated that combining 20mg of 
lenvatinib at a dose of 20mg per day with pembrolizum-
ab shows promising activity with manageable toxicity.6
In a second study, it was suggested that the multiple 
receptor TKI cabozantinib has immunomodulatory 
properties. This phase I trial reported the safety and 
clinical activity of cabozantinib (orally daily) in com-
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bination with nivolumab (IV q2w), a monoclonal IgG4 
antibody to PD-1. A total of 24 patients (6 metastat-
ic urothelial carcinomas, 4 urachal bladder carcino-
mas, 3 bladder squamous cell carcinomas, 5 germ cell 
tumors, 4 castrate-resistant prostate cancer [CRPC], 
1 RCC, and 1 trophoblastic tumor) were treated at 4 
dose levels (DL, equal distribution): DL1= cabozan-
tinib 40mg / nivolumab 1mg/kg, DL2= cabozan-
tinib 40mg / nivolumab 3mg/kg, DL3= cabozantinib 
60mg / nivolumab 1mg/kg, DL4= cabozantinib 60mg 
/ nivolumab 3mg/kg. Most dose reductions were need-
ed in patients receiving 60mg of cabozantinib. Grade 3 
AEs included neutropenia (N=3), fatigue (N=2), muco-
sitis (N=1), and vomiting (N=1). There were no grade 
≥4 toxicities. In 18 evaluable patients, the ORR (RECIST 
v1.1) was 33% including 1 complete response (CR) (a 
case of bladder squamous cell carcinoma) and 5 PRs (2 
metastatic urothelial carcinoma, 1 RCC, 1 urachal blad-
der carcinoma, 1 bladder squamous cell carcinoma, and 






























0 6 12 18 24 30
 No. at Risk:
 Cabozantinib 79 50 26 15 3 1



























0 6 12 18 24 30
 No. at Risk:
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Figure 2. PFS and OS of cabozantinib versus sunitinib as first-line therapy in mRCC.5 Top. PFS was significantly longer 
in the cabozantinib group (8.2 months, 95%CI[6.2 months – 8.8 months]) vs. the sunitinib group (5.6 months, 95%CI[3.4 
months – 8.2 months]; adjusted HR[95%CI]: 0.69[0.48 – 0.99], p= 0.012). Bottom. OS was comparable between both 
therapies (26.4 months vs. 23.5 months, respectively; adjusted HR[95%CI]: 0.87[0.55 – 1.4]).
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bination of cabozantinib with nivolumab proves well 
tolerated at recommended dose of cabozantinib 40mg 
plus nivolumab 3mg/kg. Expansion studies in patients 
with mUC and RCC are planned.7
Other studies examined the potential benefit of combin-
ing targeted therapies in RCC. At ESMO 2016, two on-
going phase Ib trials in treatment-naïve mRCC patients 
(clear-cell RCC with primary tumor resected, ≥1 mea-
sureable lesion, ECOG performance status 0-1) were 
presented.
The first trial reported the preliminary safety and ef-
ficacy results from the combination of axitinib (5 mg 
orally twice daily), a TKI inhibiting VEGFR approved 
in second- or further-line, and pembrolizumab (2 mg/
kg IV q3w), a humanized monoclonal antibody that 
blocks binding of the immune-checkpoint receptor pro-
grammed death (PD)-1 to its ligand PD-L1/2. A total of 
52 patients were eligible. More than half of the patients 
(67.3%) had an ORR (RECIST v1.1) with 2 CRs and 33 
PRs. Eleven patients enrolled in the dose finding phase 
of the trial, of which 7 remained free of progression free 
at 11 months (immature median PFS data). The most 
common grade ≥3 AEs included hypertension, diar-
rhea, headache, hyponatraemia, increased alanine ami-
notransferase (ALT), and increased levels of aspartate 
aminotransferase (AST).8
A second trial evaluated the safety and tolerability of ax-
itinib (5 mg orally twice daily) and avelumab (10 mg/
kg IV infusion q2w), a fully human IgG1 antibody that 
inhibits PD-L1. At data cut-off, 6 patients were treated 
with the combination. The median duration of treat-
ment was 17.0 weeks (range 11.9 weeks – 21.7 weeks) 
for avelumab and 16.3 weeks (range 12.7 weeks – 22.7 
weeks) for axitinib. ORR (RECIST v1.1) was observed 
in 5 patients, all being PRs, and 1 patients exhibited 
stable disease with tumour shrinkage not meeting PR. 
Grade ≥3 AEs occurred in 4 patients: hypertension (N= 
2), palmar-plantar erythrodysaesthesia syndrome (N= 
1), increased lipase (N= 1), and proteinuria (N= 1).9
These results provide a rationale that both combinations 
of a potent kinase inhibitor and an immune-checkpoint 
inhibitor prove antitumor activity in various solid tu-
mors. However, combining different drugs usually leads 
to increased toxicity. Larger trials are warranted to as-
sess this issue and to randomise versus monotherapy.
Long term efficacy and Quality of Life in 
the E3805 CHAARTED trial
It was previously reported that the combination of 
docetaxel plus androgen deprivation therapy (ADT) in-
creases the OS when compared to ADT as monotherapy 
for prostate cancer (PCa) patients with a higher burden 
of disease.10 In order to see the benefit of docetaxel in 
patients with a lower volume disease longer follow-up 
is needed.10 The E3805 CHAARTED trial reported the 
long term efficacy and Quality of Life (QoL) data of 
chemo-hormonal therapy in patients with high vs. low 
volume disease. A total of 790 men were enrolled and 
randomized 1:1 to ADT alone or ADT plus docetaxel 
(75mg/m² q3w for 6 cycles within 4 months of ADT). 
The median OS was 57.6 months (95%CI[52.0 months 
– 63.9 months]) for ADT plus docetaxel as compared to 
47.2 months (95%CI [41.8 months – 52.8 months]) for 
ADT alone (HR [95%CI]: 0.73[0.59 – 0.89], p= 0.0018). 
This benefit was however only observed for patients with 
a high volume disease (HR[95%CI]: 0.63[0.50 – 0.79], 
p<0.0001), while this was not seen in patients having 
a lower disease burden (HR[95%CI]: 1.04[0.70 – 1.55], 
p= 0.86). QoL was determined using the FACT-P score 
and showed a decline in QoL from baseline to 3 months 
in patients with low volume disease receiving ADT plus 
docetaxel. The lowest FACT-P score at 12 months was 
seen in patients with high volume disease receiving ADT 
as monotherapy. Based on these findings, the combi-
nation of ADT plus docetaxel should perhaps be lim-
ited to patients with a higher volume metastatic PCa.11
Survival data and QoL with cabazitaxel 
in mCRPC
The post-hoc survival analyses and QoL data associated 
with cabazitaxel therapy in mCRPC from 2 large phase 
III studies was presented.
The FIRSTANA trial evaluated cabazitaxel vs. docetax-
el in chemotherapy-naïve mCRPC patients. A total of 
1,168 patients were randomized 1:1:1 to cabazitax-
el 20mg/m² (N=389), cabazitaxel 25mg/m² (N=388) 
or docetaxel (N=391). The primary endpoint was OS, 
while secondary objectives included safety, PFS, PSA tu-
mor response and QoL. All results concerning efficacy 
are summarized in Table 1. The rate of grade ≥3 treat-
ment-related AEs was highest in the cabazitaxel 25mg/
m² group (60.1%) when compared to cabazitaxel 20mg/
m² and docetaxel (41.2% and 46.0%, respectively). Ca-
bazitaxel 20mg/m² was associated with a greater QoL 
benefit as compared to docetaxel (p= 0.019) whereas 
this benefit was only marginal for cabazitaxel 25mg/m² 
vs. docetaxel (p= 0.063).12
The PROSELICA trial evaluated the same endpoints for 
the use of cabazitaxel in mCRPC patients previously 
treated with docetaxel. In this study, 1,200 patients 
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were randomized 1:1 to receive cabazitaxel 20mg/m² 
(N=598) or cabazitaxel 25mg/m² (N=602). All effica-
cy data from this trial are depicted in Table 1. Grade ≥3 
treatment-related AEs were also more common in this 
cohort (54.5% vs. 39.7%), although no difference in QoL, 
based on FACT-P scores, was demonstrated (p= 0.369). 
This proves that cabazitaxel 20mg/m² is non-inferior 
to the 25mg/m² regimen. Combined with the reported 
efficacy data, this favors the use of the latter regimen 
in mCRPC patients after progression on docetaxel. 13
Of note, Both studies also indicate the prognostic val-
ue of grade ≥3 neutropenia and neutrophil-lymphocyte 
ratio for OS in mCRPC patients treated with cabazitax-
el, despite prior chemotherapy regimens (Table 1).12,13
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Cabazitaxel 25 Docetaxel Cabazitaxel 20 Cabazitaxel 
25
Efficacy
Median OS (months) 24.5 25.2 24.3 13.4 14.5
Median PFS (months) 4.4 5.1* 5.3 2.9 3.5
Tumour response (%) 32.4 41.6 30.9 18.5 23.4
















































p-value <0.0001 0.0033 0.0011 <0.001 0.059
* Significantly different between the cabazitaxel 25 mg/m² and the docetaxel regimen (P= 0.037).§ Significantly different between the 
cabazitaxel 20 mg/m² and the cabazitaxel 25 mg/m² regimen (P< 0.001).
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Share your interesting clinical cases
with your colleagues!
At the Belgian Journal for Medical Oncology we are constantly
looking for clinical cases. Should you encounter an interesting
oncological case in your centre please do not hesitate to let us know.
The BJMO is an ideal platform to share your experiences
with your colleagues and underline the encountered practical pitfalls.
All article submissions are most welcome at editor@bjmo.be
Key messages for clinical practice
1. No clear outcome on the use of sunitinib as adjuvant therapy in RCC patients following 
nephrectomy with high risk for recurrence.
2. Possible use of cabozantinib as first-line therapy in mRCC patients although further comparison 
with currently approved first-line targeted agents is needed in larger trials.
3. Combination therapy of kinase inhibitors and immune-checkpoint inhibitors show promising 
results in various genitourinary tumors but needs thorough assessment of toxicity profile as well 
as extensive comparison with monotherapy.
4. ADT plus docetaxel only shows benefit in PCa patients with high volume disease whereas 
patients with low volume disease seem to exhibit loss in QoL due to this combination.
5. Cabazitaxel shows no superiority over docetaxel in chemo-naïve mCRPC patients. The difference in 
outcome between both cabazitaxel dose regimens (20 and 25 mg/m²) is also marginal, with increased 
toxicity in the 25mg/m² regimen.
6. Grade ≥3 neutropenia and neutrophil-lymphocyte ratio potentially hold prognostic value in 
chemo-naïve and pretreated mCRPC patients.
